Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Voriconazole

FDA-approved product (tablet, oral), marketed as Vfend, Voriconazole.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Voriconazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Aspergillosis
  • Bacterial Infections and Mycoses
  • Candidemia
  • Candidiasis
  • Fungal infectious disease
  • Fusariosis
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Triazole and tetrazole derivatives
FDA pharmacologic class
Azole Antifungal FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AC03; FDA class Azole Antifungal

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli36.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Voriconazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Voriconazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial

    NCT07396480 · start 2026-03-01

    Registered record
    Registry ID
    NCT07396480
    Conditions
    Venentoclax; Myeloid Malignancies; Conditioning; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; Acute Myeloid Leucemia; Myeldysplastic Syndrome (MDS)
    Interventions
    Venetoclax in combination with fludarabine and melphalan; Fludarabine and Melphalan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-03-01
    Completion
    2030-06-30
    Enrolment
    186

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVenentoclax; Myeloid Malignancies; Conditioning; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION +2 more
    InterventionVenetoclax in combination with fludarabine and melphalan; Fludarabine and Melphalan
    PhasePhase 3
    Registry statusRecruiting

  • Rezafungin Prophylaxis in Liver Transplant

    NCT06774144 · start 2025-10-15

    Registered record
    Registry ID
    NCT06774144
    Conditions
    Liver Transplant Infection; Fungal Infection
    Interventions
    Rezafungin; Standard of care antifungal prophylaxis
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Enrolling by invitation
    Start
    2025-10-15
    Completion
    2028-12
    Enrolment
    385

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Transplant Infection; Fungal Infection
    InterventionRezafungin; Standard of care antifungal prophylaxis
    PhasePhase 3
    Registry statusEnrolling by invitation

  • Single High-dose of Liposomal Amphotericin B in Combination With B/F/TAF for HIV/AIDS-associated Talaromycosis

    NCT06926569 · start 2025-05-01

    Registered record
    Registry ID
    NCT06926569
    Conditions
    HIV/AIDS-associated Talaromycosis
    Interventions
    Amphotericin B; AmBisome
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2025-05-01
    Completion
    2026-05-01
    Enrolment
    116

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV/AIDS-associated Talaromycosis
    InterventionAmphotericin B; AmBisome
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial

    NCT06510699 · start 2025-04-14

    Registered record
    Registry ID
    NCT06510699
    Conditions
    Fungal Infection; Haematological Malignancy; Blood Cancer; Infectious Disease
    Interventions
    genotype-directed dosing with dosing software based on therapeutic drug monitoring
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-04-14
    Completion
    2027-03-26
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFungal Infection; Haematological Malignancy; Blood Cancer; Infectious Disease
    Interventiongenotype-directed dosing with dosing software based on therapeutic drug monitoring
    PhasePhase 2
    Registry statusRecruiting

  • Efficacy of Voriconazole Loaded Spanlastics Gel Versus Clotriamazole Cream on Treating Vulvovaginal Candidasis

    NCT06392529 · start 2024-05-10

    Registered record
    Registry ID
    NCT06392529
    Conditions
    Breast Cancer
    Interventions
    Voriconazole Powder
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2024-05-10
    Completion
    2024-06-30
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionVoriconazole Powder
    PhaseNot recorded
    Registry statusCompleted

  • A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients

    NCT06928376 · start 2024-04-18

    Registered record
    Registry ID
    NCT06928376
    Conditions
    Acute Myeloid Leukemia; First Line Therapy
    Interventions
    Azacytidine; Cytarabine; Aclacinomycin; Chidamide; Venetoclax; Granulocyte colony-stimulating factor; "3+7"
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-04-18
    Completion
    2026-09-01
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia; First Line Therapy
    InterventionAzacytidine; Cytarabine; Aclacinomycin; Chidamide +3 more
    PhasePhase 2
    Registry statusRecruiting

  • Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia

    NCT06068621 · start 2023-03-01

    Registered record
    Registry ID
    NCT06068621
    Conditions
    Acute Myeloid Leukemia
    Interventions
    Azacytidine; Cytarabine; Aclacinomycin; Chidamide; Venetoclax; Granulocyte colony-stimulating factor; "3+7"
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2023-03-01
    Completion
    2025-08-31
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia
    InterventionAzacytidine; Cytarabine; Aclacinomycin; Chidamide +3 more
    PhasePhase 2
    Registry statusCompleted

  • Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia

    NCT05918198 · start 2023-02-01

    Registered record
    Registry ID
    NCT05918198
    Conditions
    Acute Myeloid Leukemia
    Interventions
    Ven+CAG
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-02-01
    Completion
    2025-12-31
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia
    InterventionVen+CAG
    PhasePhase 2
    Registry statusUnknown

  • Effect of Azole/Echinocandin Use on Tacrolimus Pharmacokinetics

    NCT06044558 · start 2022-09-01

    Registered record
    Registry ID
    NCT06044558
    Conditions
    Kidney Transplant Patients
    Interventions
    Combined with voriconazole; Combined with caspofungin; Tacrolimus-alone treatment
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-09-01
    Completion
    2023-06-01
    Enrolment
    507

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Transplant Patients
    InterventionCombined with voriconazole; Combined with caspofungin; Tacrolimus-alone treatment
    PhaseNot recorded
    Registry statusCompleted

  • The Antibiogram and Outcomes of Antimicrobial Regimens in Microbial Keratitis: A Prospective Cohort Study

    NCT05655689 · start 2021-12-31

    Registered record
    Registry ID
    NCT05655689
    Conditions
    Bacterial Keratitis; Fungal Keratitis; Mixed Bacterial and Fungal Keratitis; Microbial Keratitis
    Interventions
    Moxifloxacin Ophthalmic 0.5% Ophthalmic Solution; Ceftazidime 5% + vancomycin 5%; Gentamicin 1.4% + vancomycin 5%; Natamycin 5% Oph Susp; Voriconazole 1%; Natamycin 5% + voriconazole 1%; Natamycin 5%+ ceftazidime 5% + vancomycin 5%; Voriconazole 1% + ceftazidime 5% + vancomycin 5%
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-12-31
    Completion
    2023-01-01
    Enrolment
    123

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Keratitis; Fungal Keratitis; Mixed Bacterial and Fungal Keratitis; Microbial Keratitis
    InterventionMoxifloxacin Ophthalmic 0.5% Ophthalmic Solution; Ceftazidime 5% + vancomycin 5%; Gentamicin 1.4% + vancomycin 5%; Natamycin 5% Oph Susp +4 more
    PhaseNot recorded
    Registry statusCompleted

  • Au-Ag-Cu2O NG With PTT Anti Drug-resistant Microbial Keratitis

    NCT05268718 · start 2021-08-01

    Registered record
    Registry ID
    NCT05268718
    Conditions
    Keratitis, Ulcerative; Antibiotic Resistance, Microbial; Photothermal Therapy
    Interventions
    Hollow gold and silver alloy cuprous oxide shell nano-shell hydrogel; Voriconazole eye drops; Normal saline
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Unknown
    Start
    2021-08-01
    Completion
    2024-07-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKeratitis, Ulcerative; Antibiotic Resistance, Microbial; Photothermal Therapy
    InterventionHollow gold and silver alloy cuprous oxide shell nano-shell hydrogel; Voriconazole eye drops; Normal saline
    PhaseEarly phase 1
    Registry statusUnknown

  • Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies

    NCT04865419 · start 2021-06-11

    Registered record
    Registry ID
    NCT04865419
    Conditions
    Haematological Malignancies
    Interventions
    AZD0466; Voriconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2021-06-11
    Completion
    2023-08-08
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHaematological Malignancies
    InterventionAZD0466; Voriconazole
    PhasePhase 1
    Registry statusTerminated

  • Pharmacokinetic Profile of Voriconazole Inhalation Powder in Adult Subjects With Asthma

    NCT04576325 · start 2020-11-15

    Registered record
    Registry ID
    NCT04576325
    Conditions
    Asthma
    Interventions
    Voriconazole Inhalation Powder; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-11-15
    Completion
    2021-11-12
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionVoriconazole Inhalation Powder; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

    NCT04278404 · start 2020-03-05

    Registered record
    Registry ID
    NCT04278404
    Conditions
    Coronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension; Pain; Hyperphosphatemia; Primary Hyperaldosteronism; Edema; Hypokalemia; Heart Failure; Hemophilia; Menorrhagia; Insomnia; Pneumonia; Skin Infection; Arrythmia; Asthma in Children; Bronchopulmonary Dysplasia; Adrenal Insufficiency; Fibrinolysis; Hemorrhage; Attention Deficit Hyperactivity Disorder; Multisystem Inflammatory Syndrome in Children (MIS-C); Kawasaki Disease; Coagulation Disorder; Down Syndrome
    Interventions
    The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2020-03-05
    Completion
    2026-12
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension +22 more
    InterventionThe POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    PhaseNot recorded
    Registry statusRecruiting

  • Single Ascending Dose and Multiple Ascending Dose Study of Voriconazole Inhalation Powder in Healthy Adult Subjects

    NCT04872231 · start 2019-11-22

    Registered record
    Registry ID
    NCT04872231
    Conditions
    Healthy
    Interventions
    Voriconazole Inhalation Powder; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-11-22
    Completion
    2020-08-26
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionVoriconazole Inhalation Powder; Placebo
    PhasePhase 1
    Registry statusCompleted